Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InSTINCT: Dual vs Triple Therapy in HIV
NCT04076423Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir, emtricitabine, tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundación SEIMC-GeSIDA. Started Oct 2019; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04076423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076423.